Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)

TEL-AVIV, Israel, July 30, 2024 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending an extension to the existing ind...

2024-07-30 09:00 3320

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52,...

2024-07-29 23:18 2264

A.MENARINI, CARiNG PHARMACY AND ACT4HEALTH JOIN FORCES TO DRIVE MILD COGNITIVE IMPAIRMENT EARLY DETECTION WITH A FREE VISUAL COGNITIVE ASSESSMENT TEST

- Awareness and early-stage detection of Mild Cognitive Impairment (MCI) for prevention. - Free Visual Cognitive Assessment Test (VCAT) screening at selected CARiNG Pharmacy Malaysia outlets. KUALA LUMPUR, Malaysia, July 29, 2024 /PRNewswire/ -- A. Menarini, a wholly owned subsidiary of the M...

2024-07-29 11:20 2181

A.MENARINI, CARiNG PHARMACY AND ACT4HEALTH JOIN FORCES TO DRIVE MILD COGNITIVE IMPAIRMENT EARLY DETECTION WITH A FREE VISUAL COGNITIVE ASSESSMENT TEST

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

* The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melano...

2024-07-26 23:21 5695

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

MHX Jakarta 18-21 July 2024 Wrapped Up with Record Turnout, High Leads Generation and Strategic Partnerships

JAKARTA, Indonesia, July 26, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) achieved impressive results in numerous fronts inJakarta! MHTC is the pioneer in organising healthcare expo inIndonesia and the inaugural event was in Semarang in 2012. MHTC has successfully organised two ...

2024-07-26 21:02 5852

MHX Jakarta 18-21 July 2024 Wrapped Up with Record Turnout, High Leads Generation and Strategic Partnerships

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer

* Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved inEurope for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international approval of aChina domestic anti-PD-L1 mAb. * The Eur...

2024-07-26 20:16 9703

Vantage Markets Reveals "The Future of HealthTech" in the Latest Episode of The Vantage View

PORT VILA, Vanuatu, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker, Vantage Markets

2024-07-26 17:05 2334

Vantage Australia Explores HealthTech's Future in the Latest Episode of The Vantage View

SYDNEY, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker, Vantage Markets

2024-07-26 17:05 3202

Vantage Australia Explores HealthTech's Future in the Latest Episode of The Vantage View

Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development

SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2024-07-26 09:33 2831

Australasian College of Pharmacy and MedAdvisor Solutions Launch MedAdvisor software training for the Queensland Community Pharmacy Scope of Practice Pilot

Uplifting pharmacists' role in primary care and positioning pharmacies as essential care destinations in local communities CAMBERWELL, Australia, July 25, 2024 /PRNewswire/ -- MedAdvisor Solutions and the Australasian College of Pharmacy today announced the launch of the MedAdvisor software tra...

2024-07-25 05:00 2115

Telix Successfully Prices A$650 Million Convertible Bonds

MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully pricedA$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bond...

2024-07-24 07:51 1823

Telix Announces A$600 Million Convertible Bonds Offering

MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering ofA$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds)...

2024-07-23 16:35 1742

Linical Named Best Global CRO by Global Health & Pharma Magazine

OSAKA, Japan, July 23, 2024 /PRNewswire/ -- Linical, a global Contract Research Organization (CRO) for full-service drug development, has been awarded the title ofBest Global CRO 2024 by Global Health & Pharma (GHP) Magazine. The award comes as part of the publication's annual Global Excellence A...

2024-07-23 09:00 2014

QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs

SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX , a computational drug discovery company, today announced a collaboration with Prelude Therapeutics , a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncology targets....

2024-07-23 08:00 1975

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

* Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol) * Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care's commercial platform to grow Movantik volume in the U.S. while reducing gross-to-net a...

2024-07-23 01:23 2220

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

SHANGHAI, July 22, 2024 /PRNewswire/ -- The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovativ...

2024-07-22 19:48 2507

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

* Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0...

2024-07-22 19:00 2382

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first Chinese patient has be...

2024-07-22 09:00 1922

Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2024-07-22 08:00 3014

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

* Financing led by LongRiver Investments with participation by new and existing global investment funds * Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery platform in CNS and beyond SHANGHAI, July 19, 2024 /...

2024-07-19 12:30 2689

1 ... 8 9 101112 13 14 ... 187